<p>安德魯·布拉克曼因多種因素給予了 Quest Diagnostics 買入評級，這些因素突顯了該公司的強勁表現和良好的前景。該公司在第三季度報告中交出了積極的業績，超出了關鍵指標的預期。這一表現得益於多個有利趨勢，包括使用率的提高、價格的穩定以及成功的併購。</p>
<p>Quest Diagnostics 還展示了令人印象深刻的有機收入增長，超出了市場共識預期。公司的調整後營業利潤率和每股收益符合或高於預期，進一步鞏固了其財務健康。此外，公司提高了全年業績指引，顯示出對持續增長的信心。這些因素共同證明了 Quest Diagnostics 股票的溢價估值，支持了買入評級。</p>
<p>在 10 月 17 日發佈的另一份報告中，瑞穗證券也維持了該股票的買入評級，目標價為 210.00 美元。</p>

奎斯特診療

<p>安德魯·布拉克曼對 Quest Diagnostics 給予了買入評級，理由是其第三季度業績強勁，超出預期。主要驅動因素包括使用率增加、價格穩定以及成功的併購。該公司報告了令人印象深刻的有機收入增長，並上調了全年業績指引，進一步鞏固了其財務健康狀況。瑞穗證券也維持了買入評級，目標價為 210 美元。這些因素支持了 Quest Diagnostics 股票的溢價估值</p>

<p>Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Quest Diagnostics’ strong performance and promising outlook. The company delivered positive results in its third-quarter report, surpassing expectations across key metrics. This performance was driven by several favorable trends, including increased utilization, stable pricing, and successful mergers and acquisitions.</p>
<div class="lb-trans"><p>安德魯·布拉克曼因多種因素給予了 Quest Diagnostics 買入評級，這些因素突顯了該公司的強勁表現和良好的前景。該公司在第三季度報告中交出了積極的業績，超出了關鍵指標的預期。這一表現得益於多個有利趨勢，包括使用率的提高、價格的穩定以及成功的併購。</p>
</div><p>Quest Diagnostics also demonstrated impressive organic revenue growth, which exceeded consensus estimates. The company’s adjusted operating margin and earnings per share were in line with or above expectations, further solidifying its financial health. Additionally, the company raised its full-year guidance, indicating confidence in continued growth. These factors collectively justify the premium valuation of Quest Diagnostics’ shares, supporting the Buy rating.</p>
<div class="lb-trans"><p>Quest Diagnostics 還展示了令人印象深刻的有機收入增長，超出了市場共識預期。公司的調整後營業利潤率和每股收益符合或高於預期，進一步鞏固了其財務健康。此外，公司提高了全年業績指引，顯示出對持續增長的信心。這些因素共同證明了 Quest Diagnostics 股票的溢價估值，支持了買入評級。</p>
</div><p>In another report released on October 17, Mizuho Securities also maintained a Buy rating on the stock with a $210.00 price target.</p>
<div class="lb-trans"><p>在 10 月 17 日發佈的另一份報告中，瑞穗證券也維持了該股票的買入評級，目標價為 210.00 美元。</p>
</div>

奎斯特診療：強勁的業績表現和樂觀的前景證明了買入評級的合理性